An Open-label, Phase I Study to Evaluate the Relative Bioavailability, Food Effect and Pharmacokinetic Linearity of 2 New Tablet Formulations (Adult and Pediatric) of Selitrectinib (BAY 2731954) in Relative to Oral Suspension and the Liquid Service Formulation in Healthy Adult Participants
Latest Information Update: 26 Aug 2021
Price :
$35 *
At a glance
- Drugs Selitrectinib (Primary) ; Selitrectinib
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Bayer
- 04 Aug 2021 Status changed from recruiting to completed.
- 06 May 2021 Planned End Date changed from 25 Jun 2021 to 9 Jul 2021.
- 06 May 2021 Planned primary completion date changed from 22 May 2021 to 9 Jul 2021.